Exagen is actively seeking partnerships with other businesses and institutions. Collaboration may include licensing our biomarkers or working together to commercialize our genomic technology and diagnostic tests. For further information please contact: BusinessDevelopment@exagen.com 866.392.4361



Exagen formed an exclusive sales and marketing partnership with Endochoice, Inc. in December 2009 to promote its proprietary IBD and IBS diagnostic tests to U.S. gastroenterologists. EndoChoice delivers innovative products and services to GI professionals, and through recent acquisitions is taking a lead in GI diagnostic tests and high-quality anatomic pathology services. The partnership will capitalize on EndoChoice's nationwide sales force and client relationships to provide Exagen's highly accurate, non-invasive diagnostic tests to a wide group of physicians.



Clinical Reference Laboratory (CRL) has been an Exagen partner since April 2009. Their experience in high throughput sample processing allows Exagen to accelerate the turnaround time of our tests.

Established in 1979, CRL offers leading-edge testing services in the areas of Molecular Diagnostics, Clinical Trials, Corporate Wellness, BioAnalytics, Toxicology, and Insurance - all under one roof at CRL's 192,000 square foot, state-of-the-art facility in Lenexa, Kansas. With a comprehensive test menu ranging from routine laboratory services to the latest in molecular testing, CRL is committed to providing high quality science with a human touch.

Over 500 employees strong and continuing to grow; Over 4,000,000 samples processed a year; Capacity of over 25,000 samples daily; Over 80,000,000 tests analyzed annually; 95% of samples processed within 24 hours - the most rapid turnaround time in the industry; Unparalleled customer service and responsiveness Ongoing technical innovation that directly benefits your bottom line .



Exagen has completed a broad agreement with the University of New Mexico Health Sciences Center (UNMHSC) that provides for retrospective and prospective clinical studies as well as access to specialized laboratories for genomic data collection.

UNMHSC is the largest integrated health care treatment, research and education complex in New Mexico. As part of a major research university, UNMHSC's research grants and contract awards have increased by 80 percent over the past five years.



Exagen has signed an exclusive licensing agreement with the University of New Mexico's Science and Technology Corporation, giving Exagen exclusive rights to several patents for a novel FISH (fluorescence in situ hybridization) process developed at UNMHSC.

The Science and Technology Corporation (STC) at the University of New Mexico is a nonprofit corporation owned exclusively by UNM to protect and transfer faculty inventions to the commercial marketplace. STC licenses innovative technology developed at UNM, including therapeutics, diagnostics, medical devices and drug-discovery tools.